Cryoport Q1 revenue rises

ReutersMay 4, 2026 8:28 PM

View all comments（0）



Overview

U.S. temperature-controlled supply chain firm's Q1 revenue rose 16% yr/yr to $47.8 mln
Company raised full-year revenue guidance to $192 mln-$196 mln
Adjusted EBITDA loss narrowed by $2.2 mln yr/yr, reflecting improved operational discipline

Outlook

Cryoport raises full-year 2026 revenue guidance to $192 mln-$196 mln
Company expects BioServices launch in Paris in Q3 and new Santa Ana center in Q4
Cryoport anticipates multiple growth catalysts, including new therapy approvals and facility expansions

Result Drivers

CGT PROGRAM EXPANSION - Revenue from commercial cell and gene therapy programs grew 26% yr/yr, reflecting continued expansion in approved therapies
STRONG PRODUCT DEMAND - Life Sciences Products revenue rose 15% yr/yr, driven by global demand for cryogenic systems
INTEGRATED SERVICES GROWTH - Life Sciences Services revenue increased 18% yr/yr, led by 21% growth in BioStorage/BioServices

Company press release: ID:nPnc8fn90a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$10.54 mln
Q1 Gross Margin		45.80%

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"
Wall Street's median 12-month price target for Cryoport Inc is $14.00, about 35.3% above its May 1 closing price of $10.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Trump’s China Visit Boosts China Stocks Nearly 4%, Alibaba Favored by AI Bets Despite Weak Results

TradingKey - On May 13 (ET), U.S. President Trump arrived in Beijing to begin a three-day visit. Markets expect both sides to engage in dialogue on issues such as trade and technology, a move that has eased concerns over a further escalation of U.S.-China tensions.

Pricing Hiked Three Times to $185. What Gives Cerebras Confidence in Its $49B Valuation After Spurning SoftBank?

TradingKey - AI chipmaker Cerebras Systems is racing toward a US IPO with momentum far exceeding expectations, as Wall Street's fervor for the AI semiconductor sector is fully reflected in the company.

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools